macustar – Intermediate AMD:
Development of Novel Clinical Endpoints for Clinical Trials in Patients with a Regulatory and Patient Access Intention

Macustar Partners in EuropeAge-related macular degeneration (AMD) is the commonest cause of severe visual loss and blindness in Europe and affects almost 30 percent of the older population. The chronic disease progresses slowly from early AMD to intermediate AMD (iAMD) and ultimately late-stage AMD with severe and frequently irreversible visual loss of central vision.

The objectives of macustar are to characterize the functional deficit in iAMD and to develop and validate functional, structural and patient reported outcome measures for iAMD. In addition, risk factors for progression from iAMD to late AMD will be investigated.

An introduction

Dr. Hannah Dunbar explains the research in this videoDr. Hannah Dunbar is working as an optometrist at Moorfields Eye Hospital in London and is researching the effect of eye disease on a person’s everyday life at the UCL Institute of Ophthalmology. In macustar she studies the functional tests in intermediate AMD. Learn more about what motivates Hannah and what we are doing in macustar and follow this link.

This video is adapted for people with low vision.


Innovative Medicines Initiative (IMI)

Logo of the Innovative Medicines Initiative (IMI)macustar is supported by the Innovative Medicines Initiative (IMI) with a financial contribution of 8.025 million Euros, which will be complemented by an in-kind and in-cash contribution of 8.067 million Euros provided by EFPIA partners and ZEISS Meditec AG.


  • May 31, 2024: End of MACUSTAR IMI2 funding period: Thank you #Innovative Health Initiative!
  • But no worries: MACUSTAR project goes on until February 2027 thanks to funding by our EFPIA partners
  • May 5-9, 2024: Discover the latest MACUSTAR results at ARVO 2024. 3 presentations and 5 posters. Seattle, Washington, USA
  • April 8, 2024: Third regulatory interaction: Very productive discussion meeting between MACUSTAR Consortium and European Medicines Agency (EMA) on 3-years MACUSTAR longitudinal data.
  • October 6, 2023: MACUSTAR study presented at EURETINA 2023 in Amsterdam, Netherlands
  • November 25-26, 2022:  MACUSTAR Management Board Meeting in Bonn, Germany
  • September 2, 2022:  MACUSTAR study presented at EURETINA 2022 in Hamburg, Germany
  • June 27, 2022: Virtual Meeting of the MACUSTAR Scientific Advisory Board
  • June 27, 2022: MACUSTAR study extended until February 2024
  • June 23, 2022: New publication from the MACUSTAR consortium in JAMA Ophthalmology
  • May 01-04, 2022: Results of MACUSTAR cross-sectional study presented at ARVO 2022 in Denver, USA
  • March 30, 2022: New publication from the MACUSTAR consortium in British Journal of Ophthalmology
  • March 25, 2022: New publication from the MACUSTAR consortium in Translational Vision Science & Technology

Read more about these and other news …

Related Links

In this section you can find related linkThe macustar Project, Fact sheet of the macustar project on the website of the Innovative Medicines Initiative (IMI), Information about AMD
and other related links